| MeSH term | MeSH ID | Detail |
|---|---|---|
| Acne Vulgaris | D000152 | 35 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Alopecia Areata | D000506 | 6 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Olfaction Disorders | D000857 | 17 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Celiac Disease | D002446 | 16 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Cholelithiasis | D002769 | 16 associated lipids |
| Cholestasis | D002779 | 23 associated lipids |
| Chondrodysplasia Punctata | D002806 | 8 associated lipids |
| Chronic Disease | D002908 | 7 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Coronary Artery Disease | D003324 | 47 associated lipids |
| Coronary Disease | D003327 | 70 associated lipids |
| Demyelinating Diseases | D003711 | 15 associated lipids |
(e,e,e,e)-squalene
(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
Cross Reference
Introduction
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with (e,e,e,e)-squalene?
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
PubChem Associated disorders and diseases
What pathways are associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with (e,e,e,e)-squalene?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with (e,e,e,e)-squalene?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with (e,e,e,e)-squalene
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Michael-Jubeli R et al. | High-temperature gas chromatography-mass spectrometry for skin surface lipids profiling. | 2011 | J. Lipid Res. | pmid:20952798 |
| Lama-Muñoz A et al. | New hydrothermal treatment of alperujo enhances the content of bioactive minor components in crude pomace olive oil. | 2011 | J. Agric. Food Chem. | pmid:21265536 |
| Ellebedy AH et al. | Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. | 2011 | Proc. Natl. Acad. Sci. U.S.A. | pmid:21270336 |
| Morel S et al. | Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. | 2011 | Vaccine | pmid:21256188 |
| Sarpietro MG et al. | Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. | 2011 | Int J Pharm | pmid:21219999 |
| Brasser AJ et al. | Presence of wax esters and squalene in human saliva. | 2011 | Arch. Oral Biol. | pmid:21247555 |
| Arguedas A et al. | Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. | 2011 | Hum Vaccin | pmid:21285531 |
| Manuel O et al. | Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. | 2011 | Clin. Infect. Dis. | pmid:21288852 |
| Raouane M et al. | Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. | 2011 | J. Med. Chem. | pmid:21561161 |
| Nowosielski M and Hoffmann M | Do the substituent effects affect conformational freedom of squalene in hopene biosynthesis? | 2011 | J Mol Model | pmid:21562825 |
| Hernández-GarcÃa I et al. | [Adverse events after administration of A/H1N1 vaccine to patients]. | 2011 | Med Clin (Barc) | pmid:20199781 |
| Fenoglio D et al. | MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine. | 2011 | J Prev Med Hyg | pmid:22010544 |
| Precioso AR et al. | A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. | 2011 | Vaccine | pmid:21945258 |
| Pariani E et al. | Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. | 2011 | Vaccine | pmid:21974995 |
| Andrews NJ et al. | Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. | 2011 | Vaccine | pmid:21875635 |
| Vesikari T et al. | Oil-in-water emulsion adjuvant with influenza vaccine in young children. | 2011 | N. Engl. J. Med. | pmid:21995388 |
| Fox CB et al. | Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions. | 2011 | Pharm Dev Technol | pmid:20550484 |
| Celia C et al. | Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. | 2011 | Expert Opin Drug Deliv | pmid:22077480 |
| Tsai TF | MF59 adjuvanted seasonal and pandemic influenza vaccines. | 2011 | Yakugaku Zasshi | pmid:22129867 |
| Puig-Barberà J et al. | MF59™-adjuvanted seasonal influenza vaccine in young children. | 2011 | Expert Rev Vaccines | pmid:22043952 |
| Viganò A et al. | Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. | 2011 | Clin. Vaccine Immunol. | pmid:21795458 |
| Huijskens E et al. | Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. | 2011 | Clin. Vaccine Immunol. | pmid:21795459 |
| Pollard AJ and Hill AV | Antibody repertoire: embracing diversity. | 2011 | Sci Transl Med | pmid:21795586 |
| Okike IO et al. | The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. | 2011 | Vaccine | pmid:21742005 |
| Kowert BA and Watson MB | Diffusion of organic solutes in squalane. | 2011 | J Phys Chem B | pmid:21780767 |
| Mackay D and Jones PJ | Evaluation of methods for the determination of cholesterol absorption and synthesis in humans. | 2011 | Atherosclerosis | pmid:21763652 |
| Jawaid AM et al. | Shape-controlled colloidal synthesis of rock-salt lead selenide nanocrystals. | 2011 | ACS Nano | pmid:21770427 |
| Oliaro-Bosso S et al. | Characterization of the channel constriction allowing the access of the substrate to the active site of yeast oxidosqualene cyclase. | 2011 | PLoS ONE | pmid:21811565 |
| Bildstein L et al. | Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. | 2011 | Eur J Pharm Biopharm | pmid:21784150 |
| Della Cioppa G et al. | Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. | 2011 | Vaccine | pmid:21906647 |
| Fox CB et al. | Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. | 2011 | Vaccine | pmid:21906648 |
| Zuccotti GV et al. | Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. | 2011 | Diabet. Med. | pmid:21916971 |
| Kajaste-Rudnitski A et al. | Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. | 2011 | AIDS | pmid:21150561 |
| Launay O et al. | Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. | 2011 | J. Infect. Dis. | pmid:21628666 |
| Piccialli V et al. | Isolation of a bis-iodurated tetra-THF as a trace product from the oxidation of squalene with RuOâ‚„ and its double ring expansion to a novel bis-THF-bis-THP compound. | 2011 | Molecules | pmid:21709619 |
| Iannazzo S | Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy. | 2011 | J Prev Med Hyg | pmid:21710816 |
| Seubert A et al. | Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. | 2011 | Proc. Natl. Acad. Sci. U.S.A. | pmid:21690334 |
| Khurana S et al. | MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. | 2011 | Sci Transl Med | pmid:21632986 |
| Zhang LW et al. | Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions. | 2011 | Int J Nanomedicine | pmid:21556344 |
| Lens M and Podesta Marty MH | Assessment of the kinetics of the antioxidative capacity of topical antioxidants. | 2011 | J Drugs Dermatol | pmid:21369642 |
| Cristiani C et al. | Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. | 2011 | Vaccine | pmid:21396903 |
| Tabache F et al. | Acute polyarthritis after influenza A (H1N1) immunization. | 2011 | Joint Bone Spine | pmid:21444232 |
| Sun Y et al. | A reproducible in-vivo model of lymphatic malformation in rats. | 2011 | J. Comp. Pathol. | pmid:21419420 |
| Meier S et al. | Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. | 2011 | Vaccine | pmid:21419775 |
| Réjiba S et al. | Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. | 2011 | Nanomedicine | pmid:21419876 |
| Banzhoff A et al. | Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. | 2011 | Hum Vaccin | pmid:21422814 |
| Siedenburg G and Jendrossek D | Squalene-hopene cyclases. | 2011 | Appl. Environ. Microbiol. | pmid:21531832 |
| Tsai TF et al. | Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. | 2011 | Scand. J. Infect. Dis. | pmid:21534891 |
| Esposito S et al. | Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. | 2011 | Pediatrics | pmid:21464195 |
| Esposito S et al. | An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. | 2011 | Nephrol. Dial. Transplant. | pmid:20974645 |